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EDITORIALS
Glucocorticoids and Airway Smooth Muscle: A Few More Answers,
Still More Questions
Glucocorticoids (oral and inhaled corticosteroids) have been critical
for the management of asthma symptoms owing to their exceptional
therapeutic efﬁcacy in mitigating airway inﬂammation.
Glucocorticoids exert therapeutic effects in asthma primarily via
their genomic actions in resident or invading lung cells (1), either
by negatively regulating the expression of genes that promote
inﬂammation or by inducing genes that inhibit inﬂammation.
Although inhalation of corticosteroids provides efﬁcient control
of exacerbations in a large number of patients with asthma,
corticosteroids have limited efﬁcacy in many patients with asthma
whose disease is severe or refractory (steroid-resistant asthma) (1).
Multiple mechanisms have been proposed to explain the
compromised glucocorticoid response in distinct cell types
associated with asthma pathology, but the precise molecular
mechanisms remain ill deﬁned.
To date, most studies have emphasized immune cells and
epithelial cells as the key targets of glucocorticoid actions in the
asthmatic lung. However, glucocorticoids have potentially
important immunomodulatory effects on airway smooth muscle
(ASM) cells. Speciﬁcally, glucocorticoid actions in ASM can affect
both airway inﬂammation (i.e., the immunomodulatory role of
ASM) and airway remodeling (2–6). Glucocorticoids can also
regulate the contractile function of ASM by 1) reducing cholinergic
hypersensitivity in the airways, possibly through regulation of the
expression of G protein–coupled receptors (muscarinic: M2, M3;
and histamine: H1) that mediate airway contraction (7–9), or
2) augmenting airway relaxation through upregulation of b2AR
(b2 adrenergic receptor) and modulation of adenylyl cyclase
activity (10, 11). Although studies over the last decade have
provided signiﬁcant insight into the complex molecular
interactions of glucocorticoids in ASM cells, whether ASM
from individuals with asthma responds differently to
glucocorticoids is unknown, as is the contribution of this response
to the phenomenon of steroid resistance in individuals with
asthma.
In this issue of the Journal, Kan and colleagues (pp. 110–120)
take an important step toward addressing this problem by
characterizing the glucocorticoid-regulated transcriptome of ASM
derived from patients with severe asthma (12). Speciﬁcally, the
authors compare differences in mRNA abundance in ASM cells
derived from donors with fatal asthma and donors without asthma,
treated or not treated with budesonide. Additionally, the authors
compare the dataset generated in this experiment with the
transcriptomic proﬁle of glucocorticoid response in other cell types
(from a publicly available database), and identify signatures unique
to ASM.
Several interesting observations are reported. Somewhat
surprisingly, the transcriptome proﬁles were highly similar in ASM
from donors with asthma and those without asthma, both at baseline
and after stimulation with budesonide. In ASM cells from both
donor cohorts, glucocorticoid-regulated genes such as TSC22D3,
CRISPLD2, and KLF15 were signiﬁcantly upregulated, which is
consistent with previous studies that examined glucocorticoid
responses in bronchial biopsies and isolated ASM cells (13–15).
Similarly, FKBP5, which has been previously reported as a negative
regulator of glucocorticoid response in individuals with asthma,
was also signiﬁcantly upregulated (13). Two genes, CCK
(cholecystokinin) and PMEL (premelanosome protein), were
differentially expressed between the cohorts with and without
asthma. The functions of these genes in ASM are poorly deﬁned,
and additional studies focused on examining their role in rendering
ASM cells glucocorticoid resistant are essential to establish their
physiological relevance in the development of steroid resistance in
the disease state.
Although the paper by Kan and colleagues is a critical step
toward identifying glucocorticoid-regulated molecular networks
that are differentially regulated in ASM cells from patients with
severe asthma, the clinical signiﬁcance of these observations is
unclear and remains to be determined in future work. As duly noted
by the authors, the ASM cells were derived from postmortem
specimens with cursory background information lacking speciﬁc
clinical data or comments on steroid usage and resistance, if any. It is
also essential to note here that isolated ASM cells retain molecular
and physiological traits that are reﬂective of their behavior in vivo
and have been used extensively in basic and translational research.
Understandably, the ASM cells used in the current study were
isolated from tracheae or large bronchi. However, ASM cells
from smaller airways play a crucial role in inﬂuencing airway
inﬂammation, remodeling, and resistance, and may respond
differently to glucocorticoids and be equally or more important
than large-airway ASM cells in contributing to steroid resistance in
patients with asthma. Finally, a validation of these targets using a
secondary approach (such as real-time qPCR) or biochemical
analysis of proteins is also lacking. Notwithstanding these
limitations, the current effort by Kan and colleagues shows that
glucocorticoid responses are altered in ASM cells from individuals
with severe asthma.
Understanding the mechanisms that contribute to steroid
resistance in patients with asthma is a profound challenge that is
mademore difﬁcult not only by the complexity of the disease asthma
per se but also by the fact that multiple cell types contribute to
asthma pathobiology, and the function of each of these cells is
regulated by glucocorticoids. Although the clinical effect of steroid
treatment can be readily assessed, the success or failure of steroid
treatment relies on the sum of the effects of the drug on multiple
cells, and how steroids impact the singular and cooperative actions
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of the cells that cause asthma. Given that it is extremely difﬁcult to
decipher the relative contributions of individual cell types to drug
responses in integrative human studies (i.e., most clinical research),
and despite the inherent limitations of in vitro studies (16), a logical
approach to understanding these mechanisms is to pursue more
reductionist studies in individual cell types and then attempt
to piece data from such studies into a understanding of the
gestalt. Accordingly, computational biology methods to analyze
transcriptome data (and other omics-based approaches) along with
extensive clinical and patient phenotype data would greatly serve
this purpose and clearly represent an important path for future
research.
Careful consideration of the limitations of reductionist/
in vitro studies is necessary to inform study design and enable
interpretation. Relevant to Kan and colleagues, the source of cells
from patients with asthma is an important consideration. Cells
obtained from ASM tissue collected after an autopsy have potential
viability concerns, but perhaps more importantly, the ability to
ultimately match experimental data with a patient’s clinical proﬁle
or disease phenotype is often limited compared with what can
achieved in prospective studies in which tissue can be procured
from (live) patients. Yet, the latter situation also has limitations,
in that tissue procurement occurs via bronchial biopsies,
which are highly variable with respect to the amount and viability
of ASM collected, and involve a fairly invasive (and expensive)
protocol.
Despite these and other technical and design challenges of
cell-based studies, studies such as those conducted by Kan
and colleagues are critical to the slow inductive process of acquiring
sufﬁcient data to gain insight into the pathobiology of asthma
and a patient’s response to asthma drugs. Ultimately, the
reﬁnement of experimental designs coupled with better technology
will grow the database and advance this ﬁeld of study. n
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